Yes, Medicaid covers buprenorphine in all 50 states. Since October 2020, federal law has required every state Medicaid program to cover FDA-approved medications for opioid use disorder, including buprenorphine, methadone, and naltrexone. This mandate came from the SUPPORT Act, signed in 2018, and it applies to all formulations of these medications that the FDA has approved for treating opioid use disorder.
Why Coverage Is Mandatory
The SUPPORT Act added medication-assisted treatment to the legal definition of “medical assistance” under Medicaid. That means states cannot simply choose to exclude buprenorphine the way they might with other medications. The law also requires coverage of counseling and behavioral therapy services provided alongside these medications.
There is one narrow exception: a state could have applied for an exemption before October 2020 if it could prove there weren’t enough qualified providers or treatment facilities to make statewide coverage feasible. In practice, this was a difficult standard to meet, and the overwhelming majority of states moved forward with full coverage.
What You Might Still Pay
Coverage doesn’t always mean zero cost. Most state Medicaid programs place buprenorphine/naloxone combination products (the generic version of Suboxone) on their preferred drug lists. If your prescriber writes for a brand-name product when a generic is available, you may need a “brand medically necessary” prior authorization, and the pharmacy claim could be flagged if it exceeds cost thresholds. Sticking with the generic sublingual tablet or film is typically the smoothest path through the system.
Copays for Medicaid prescriptions are generally very low, often a few dollars or less, and some enrollees are exempt from copays entirely. The specifics depend on your state and your eligibility category.
Prior Authorization Requirements
Even though buprenorphine is a mandatory benefit, many states still require prior authorization before your pharmacy can fill the prescription. This means your provider submits paperwork to Medicaid justifying the prescription, and the state approves it before dispensing. The process can take hours to days, which creates a real barrier for someone in withdrawal who needs medication quickly.
Some states have moved to eliminate prior authorization for buprenorphine entirely. Research on California and Illinois found that lifting prior authorization requirements led to a measurable increase in prescription fills in one of the two states. The trend nationally has been toward reducing these hurdles, but progress is uneven.
Dosage Caps and Quantity Limits
About a third of state Medicaid programs set a maximum daily dosage for buprenorphine, which can affect your treatment if you need a higher dose. The most common cap is 24 mg per day, used by states including Alaska, Idaho, Montana, Pennsylvania, Virginia, and Utah, with no built-in option to go higher. A smaller group of states, including Georgia, Kentucky, Oklahoma, and Vermont, cap coverage at 16 mg per day.
Wyoming has an unusual step-down policy: a 16 mg daily limit for the first two years of treatment, dropping to 8 mg after that. If your prescriber believes you need a dose above your state’s cap, they typically have to request an exception through the prior authorization process. About 22% of states require additional steps before approving daily doses above 16 mg.
Counseling Requirements
Twelve states and the District of Columbia require patients prescribed buprenorphine for opioid use disorder to participate in counseling, with three of those states specifying a minimum frequency. This is a state-level policy decision, not a federal requirement. Clinical guidelines from major medical organizations generally recommend that buprenorphine access should not depend on whether a patient is also attending counseling, since the medication itself reduces overdose risk and cravings regardless of therapy participation. Some advocacy groups have called on states to drop mandatory counseling rules as an unnecessary barrier to treatment.
Treatment Duration Limits
Nearly all state Medicaid programs have eliminated lifetime limits on buprenorphine treatment. This shift happened partly in response to federal mental health parity rules, which require addiction treatment benefits to be comparable to medical and surgical benefits. If a state capped buprenorphine at, say, two years but didn’t impose similar limits on medications for diabetes or high blood pressure, that would likely violate parity law.
The practical result is that most Medicaid enrollees can stay on buprenorphine for as long as their prescriber considers it medically appropriate. Long-term use is well supported by evidence: research in Medicaid populations has found that sustained buprenorphine treatment is associated with better health outcomes compared to shorter courses.
Telehealth Prescribing
You can start buprenorphine treatment through a telehealth visit. Federal agencies finalized a rule making permanent the telemedicine flexibilities that were originally introduced during the COVID-19 pandemic. This means a provider can evaluate you and prescribe buprenorphine over video or phone without requiring an in-person visit first. Whether your state Medicaid program covers the telehealth visit itself, and under what conditions, varies by state, but the prescribing side is now settled at the federal level.
How to Check Your Specific Coverage
Because Medicaid is administered state by state, the details of your coverage depend on where you live. The fastest way to find out exactly what applies to you is to call the number on the back of your Medicaid card and ask about buprenorphine coverage, including whether prior authorization is required and which formulations are preferred. You can also search your state’s Medicaid preferred drug list online, which will show whether generic buprenorphine/naloxone is covered without extra steps. SAMHSA’s helpline (1-800-662-4357) can help connect you with local providers who accept Medicaid and prescribe buprenorphine.